This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2021 Jan 26;96(4):175-176.

doi: 10.1212/WNL.0000000000011343. Epub 2020 Dec 11.

Nelarabine-Induced Myelotoxicity

Ajay A Madhavan¹, Carrie M Carr¹, Hassan Alkhateeb¹, Nathan P Staff¹, Elie Naddaf²

Affiliations

Affiliations

¹ From the Departments of Radiology (A.A.M., C.M.C.), Hematology and Oncology (H.A.), and Neurology (N.P.S., E.N.), Mayo Clinic, Rochester, MN.
² From the Departments of Radiology (A.A.M., C.M.C.), Hematology and Oncology (H.A.), and Neurology (N.P.S., E.N.), Mayo Clinic, Rochester, MN. naddaf.elie@mayo.edu.

PMID: 33310877
DOI: 10.1212/WNL.0000000000011343

Case Reports

Nelarabine-Induced Myelotoxicity

Ajay A Madhavan et al. Neurology. 2021.

. 2021 Jan 26;96(4):175-176.

doi: 10.1212/WNL.0000000000011343. Epub 2020 Dec 11.

Authors

Ajay A Madhavan¹, Carrie M Carr¹, Hassan Alkhateeb¹, Nathan P Staff¹, Elie Naddaf²

Affiliations

¹ From the Departments of Radiology (A.A.M., C.M.C.), Hematology and Oncology (H.A.), and Neurology (N.P.S., E.N.), Mayo Clinic, Rochester, MN.
² From the Departments of Radiology (A.A.M., C.M.C.), Hematology and Oncology (H.A.), and Neurology (N.P.S., E.N.), Mayo Clinic, Rochester, MN. naddaf.elie@mayo.edu.

PMID: 33310877
DOI: 10.1212/WNL.0000000000011343

No abstract available

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.